Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias

Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias

US Patent 12227588 · Granted Feb 18, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosi2025
Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosi2025
Fully-human T-cell receptor specific for the 369-377 epitope derived from the He2025
Treatment of a canine CD20 positive disease or condition using a canine CD20-spe2025
Switch costimulatory receptors2025
Compositions and methods for generating a persisting population of T cells usefu2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric a2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric a2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric a2025
Altering gene expression in cart cells and uses thereof2025
Use of trans-signaling approach in chimeric antigen receptors2025
Use of trans-signaling approach in chimeric antigen receptors2025